Full-Time

Corporate & Brand Marketing Manager

Confirmed live in the last 24 hours

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

51-200 employees

Develops RNAi-based therapies for genetic diseases

Biotechnology
Healthcare

Compensation Overview

$120k - $140kAnnually

Senior

Pasadena, CA, USA

This role is onsite 5x a week at Arrowhead’s Corporate Headquarters in Pasadena, CA.

Category
Brand & Creative Marketing
General Marketing
Growth & Marketing
Required Skills
Social Media
Marketing
Requirements
  • Bachelor’s degree in marketing, communications, business, or a related field.
  • 5 years of pharmaceutical marketing experience
  • 2 years of experience managing external corporate marketing initiatives.
  • 2 years managing HCP branding initiatives
  • Strong cross-functional collaboration skills and the ability to lead strategic initiatives.
  • Proven experience in managing corporate marketing initiatives and driving brand growth.
  • Excellent communication, leadership, and project management skills.
Responsibilities
  • Lead the development and execution of marketing strategies for HCPs, ensuring alignment with Plozasiran’s brand positioning and messaging.
  • Oversee peer-to-peer marketing initiatives, including speaker bureau programs and HCP engagement campaigns.
  • Ensure all promotional communications to HCPs maintain consistency and comply with regulatory guidelines.
  • Drive corporate marketing campaigns, ensuring alignment with brand objectives and business goals.
  • Collaborate with cross-functional teams to integrate marketing strategies into broader corporate plans, ensuring a unified brand message.
  • Monitor campaign performance and optimize strategies to maximize ROI and brand impact.
  • Lead content development for external communications, including events, social media, and key milestones.
  • Build and maintain relationships with external partners, agencies, and vendors to ensure successful execution of marketing programs.
  • Cultivate internal and external partnerships to enhance Arrowhead’s brand presence and visibility in both HCP and corporate spheres.
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

View

Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing specific genes. The company uses RNA interference (RNAi), a natural process that reduces gene expression, to create therapies that can potentially stop or reverse the progression of diseases like cystic fibrosis and hepatitis B. Their approach involves a variety of RNA chemistries and effective delivery methods to ensure deep and lasting effects on target genes. Unlike many competitors, Arrowhead focuses specifically on RNAi-based therapies, which allows them to address medical needs that are not met by existing treatments. Their goal is to provide new options for patients suffering from genetic disorders, and they generate revenue through partnerships, licensing agreements, and future sales of their therapies after regulatory approval.

Company Stage

IPO

Total Funding

$4.7M

Headquarters

Pasadena, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Arrowhead's recent $450 million funding round provides substantial financial resources to advance its drug pipeline and expand research initiatives.
  • Positive Phase 2 data for plozasiran and the initiation of an Expanded Access Program highlight the company's commitment to addressing unmet medical needs.
  • The company's diversified pipeline, including treatments for cystic fibrosis, hepatitis B, and myotonic dystrophy, offers multiple avenues for success.

What critics are saying

  • The high costs and lengthy timelines associated with drug development could strain Arrowhead's financial resources despite recent funding.
  • Regulatory hurdles and the potential for clinical trial failures pose significant risks to the company's drug approval process.

What makes Arrowhead Pharmaceuticals unique

  • Arrowhead Pharmaceuticals leverages RNA interference (RNAi) technology to target and silence disease-causing genes, setting it apart from traditional pharmaceutical approaches.
  • The company's proprietary TRiM platform enables tissue-specific targeting, enhancing the efficacy and safety of its therapies.
  • Strategic partnerships with major pharmaceutical companies like Takeda bolster Arrowhead's credibility and expand its research capabilities.

Help us improve and share your feedback! Did you find this helpful?